HER-Seq: A Blood-based Screening Study to Identify Patients With HER2 Mutations for Enrollment Into Clinical Research Studies of Neratinib

TERMINATED

Status

1583

Enrollment

INDUSTRY

Sponsor class

Stopped The study was stopped early due to increased global access to genomic screening. It is no longer economical to continue with this particular single-gene screening protocol.

Conditions

Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer
Metastatic Cervical Cancer

Interventions

DIAGNOSTIC_TEST: Almac HER-Seq Assay

Sponsor

Puma Biotechnology, Inc.